As per Intent Market Research, the Immunoassay Market was valued at USD 33.3 billion in 2023-e and will surpass USD 48.2 billion by 2030; growing at a CAGR of 5.4% during 2024 - 2030.
The report focuses on estimating the current market potential in terms of the total addressable market for all the segments, sub-segments, and regions. In the process, all the high-growth and upcoming technologies were identified and analyzed to measure their impact on the current and future market. The report also identifies the key stakeholders, their business gaps, and their purchasing behavior. This information is essential for developing effective marketing strategies and creating products or services that meet the needs of the target market. The report also covers a detailed analysis of the competitive landscape which includes major players, their recent developments, growth strategies, product benchmarking, and manufacturing operations among others. Also, brief insights on start-up ecosystem and emerging companies is also included as part of this report.
The report will help you answer some of the most critical questions in the Immunoassay Market. A few of them are as follows:
Report Features |
Description |
Market Size (2023-e) |
USD 33.3 billion |
Forecasted Value (2030) |
USD 48.2 billion |
CAGR (2024-2030) |
5.4% |
Base Year for Estimation |
2023-e |
Historic Year |
2022 |
Forecast Period |
2024-2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
Immunoassay Market By Product (Analyzers, Reagents & Kits), By Technology (Fluoroimmnoassay, ELISA, Radioimmunoassay, Rapid Tests, CLIA, Western Blotting), By Application (Endocrinology, Bone & Mineral Disorders, Infectious Diseases, Blood Screening, Allergy Diagnostics), By End-use (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and CROs, Clinical Laboratories) |
Regional Analysis |
North America (US, Canada), Europe (Germany, France, UK, Spain, Italy & Rest of Europe), Asia Pacific (China, Japan, South Korea, India, and rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, & Rest of Latin America), Middle East & Africa (Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA) |
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
1.Introduction |
1.1.Market Definition |
1.2.Scope of the Study |
1.3.Research Assumptions |
1.4.Study Limitations |
2.Research Methodology |
2.1.Research Approach |
2.1.1.Top-Down Method |
2.1.2.Bottom-Up Method |
2.1.3.Factor Impact Analysis |
2.2.Insights & Data Collection Process |
2.2.1.Secondary Research |
2.2.2.Primary Research |
2.3.Data Mining Process |
2.3.1.Data Analysis |
2.3.2.Data Validation and Revalidation |
2.3.3.Data Triangulation |
3.Executive Summary |
3.1.Major Markets & Segments |
3.2.Highest Growing Regions and Respective Countries |
3.3.Impact of Growth Drivers & Inhibitors |
3.4.Regulatory Overview by Country |
4.Immunoassay Market, by Product (Market Size & Forecast: USD Billion, 2024 – 2030) |
4.1.Reagents & Kits |
4.1.1.IFA Reagents & Kits |
4.1.2.CLIA Reagents & Kits |
4.1.3.Western Blot Reagent & Kits |
4.1.4.Rapid Test Reagent & Kits |
4.1.5.ELISpot Reagent & Kits |
4.1.6.ELISA Reagents & Kits |
4.1.7.Other Reagents & Kits |
4.2.Analyzers |
4.2.1.By Type |
4.2.1.1.Closed-ended Systems |
4.2.1.2.Open-ended Systems |
4.2.2.By Purchase Mode |
4.2.2.1.Outright Purchase |
4.2.2.2.Rental Purchase |
5.Immunoassay Market, by Technology (Market Size & Forecast: USD Billion, 2024 – 2030) |
5.1.ELISA |
5.2.Western Blotting |
5.3.Rapid Tests |
5.4.Immunofluorescence assay (IFA) |
5.5.ELISpot |
5.6.Chemiluminescence Immunoassay (CLIA) |
5.7.Other Technologies |
6.Immunoassay Market, by Application (Market Size & Forecast: USD Billion, 2024 – 2030) |
6.1.Bone & Mineral Disorders |
6.2.Infectious Diseases |
6.3.Endocrinology |
6.4.Oncology |
6.5.Cardiology |
6.6.Blood Screening |
6.7.Autoimmune Disorders |
6.8.Allergy Diagnostics |
6.9.Toxicology |
6.10.Newborn Screening |
6.11.Other Applications |
7.Immunoassay Market, by End User (Market Size & Forecast: USD Billion, 2024 – 2030) |
7.1.Hospitals |
7.2.Clinical Laboratories |
7.3.Pharmaceutical & Biotechnology Companies and CROs |
7.4.Blood Banks |
7.5.Research Laboratories |
7.6.Home Care Settings |
8.Regional Analysis (Market Size & Forecast: USD Billion, 2024 – 2030) |
8.1.Regional Overview |
8.2.North America |
8.2.1.Regional Trends & Growth Drivers |
8.2.2.Barriers & Challenges |
8.2.3.Opportunities |
8.2.4.Factor Impact Analysis |
8.2.5.Technology Trends |
8.2.6.North America Immunoassay Market, by Product |
8.2.7.North America Immunoassay Market, by Technology |
8.2.8.North America Immunoassay Market, by Application |
8.2.9.North America Immunoassay Market, by End User |
*Similar segmentation will be provided at each regional level |
8.3.By Country |
8.3.1.US |
8.3.1.1.US Immunoassay Market, by Product |
8.3.1.2.US Immunoassay Market, by Technology |
8.3.1.3.US Immunoassay Market, by State |
8.3.1.4.US Immunoassay Market, by End User |
8.3.2.Canada |
*Similar segmentation will be provided at each country level |
8.4.Europe |
8.5.APAC |
8.6.Latin America |
8.7.Middle East & Africa |
9.Competitive Landscape |
9.1.Overview of the Key Players |
9.2.Competitive Ecosystem |
9.2.1.Platform Manufacturers |
9.2.2.Subsystem Manufacturers |
9.2.3.Service Providers |
9.2.4.Software Providers |
9.3.Company Share Analysis |
9.4.Company Benchmarking Matrix |
9.4.1.Strategic Overview |
9.4.2.Product Innovations |
9.5.Start-up Ecosystem |
9.6.Strategic Competitive Insights/ Customer Imperatives |
9.7.ESG Matrix/ Sustainability Matrix |
9.8.Manufacturing Network |
9.8.1.Locations |
9.8.2.Supply Chain and Logistics |
9.8.3.Product Flexibility/Customization |
9.8.4.Digital Transformation and Connectivity |
9.8.5.Environmental and Regulatory Compliance |
9.9.Technology Readiness Level Matrix |
9.10.Technology Maturity Curve |
9.11.Buying Criteria |
10.Company Profiles |
10.1.Abbott |
10.1.1.Company Overview |
10.1.2.Company Financials |
10.1.3.Product/Service Portfolio |
10.1.4.Recent Developments |
10.1.5.IMR Analysis |
*Similar information will be provided for other companies |
10.2.Roche |
10.3.Thermo Fisher Scientific |
10.4.Danaher |
10.5.Siemens Healthineers 10.6.Becton & Dickinson 10.7.Qiagen 10.8.Agilent Technologies 10.9.Immucor 10.10.Sysmex |
11.Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Immunoassay Market. In the process, the analysis was also done to estimate the parent market and relevant adjacencies to major the impact of them on the immunoassay Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the immunoassay ecosystem. The primary research objectives included:
A combination of top-down and bottom-up approaches was utilized to estimate the overall size of the immunoassay market. These methods were also employed to estimate the size of various subsegments within the market. The market size estimation methodology encompassed the following steps:
To ensure the accuracy and reliability of the market size estimates, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size estimates.